peptide-yy and Dyslipidemias

peptide-yy has been researched along with Dyslipidemias* in 5 studies

Reviews

1 review(s) available for peptide-yy and Dyslipidemias

ArticleYear
[The role of gut microbiota in the pathogenesis of obesity].
    Postepy higieny i medycyny doswiadczalnej (Online), 2014, Jan-24, Volume: 68

    Obesity is a disease that develops as a result of long-term positive energy balance. In recent years, the influence of gut microflora composition, as a potential factor affecting the energy balance and contributing to fat accumulation, has been studied. It seems that bacteria can affect host energy balance through several mechanisms, such as increased fermentation of undigested polysaccharides and obtaining extra energy from the portion of food, reduced expression of FIAF (fasting-induced adipocyte factor) in the enterocytes with inhibitory activity towards intestinal lipoprotein lipase, and the increased release of peptide YY that slows the intestinal motility. It is also believed that changes in the composition of gut microflora may be one of the factors that induce systemic microinflammation in the obese, an important link in the pathogenesis of obesity related complications, including dyslipidaemia, hypertension and type 2 diabetes. However, the results of previous studies are inconclusive. Many of them have been carried out in an animal model and were not confirmed in studies involving humans. These discrepancies may be due to different composition of the diet, distinct physiological gut microflora and the methodology used in these studies. The present article reviews the current literature on the potential role of gut microflora in the pathogenesis of obesity.

    Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Dyslipidemias; Energy Metabolism; Enterocytes; Gastrointestinal Motility; Gastrointestinal Tract; Humans; Hypertension; Intestines; Lipase; Microbiota; Obesity; Peptide YY

2014

Trials

1 trial(s) available for peptide-yy and Dyslipidemias

ArticleYear
Postprandial metabolic and hormonal responses of obese dyslipidemic subjects with metabolic syndrome to test meals, rich in carbohydrate, fat or protein.
    Atherosclerosis, 2010, Volume: 210, Issue:1

    The metabolic syndrome (MS) is a cluster of heterogeneous abnormalities conferring increased risk of cardiovascular diseases. Few postprandial studies have been conducted in MS individuals.. We aimed to study MS subjects with the same abnormalities: abdominal obesity, hypertriglyceridemia and low plasma HDL. We assessed postprandial variations of metabolic parameters related to obesity, dyslipidemia and glucose homeostasis.. In this randomized, double-blind, cross-over study, male MS and control subjects consumed, at separate occasions, a high carbohydrate (HC), high fat (HF) or high protein (HP) breakfast meal providing 30% of each subject's resting energy expenditure.. Appetite hormones peptide YY and ghrelin did not differ between-subject groups. Interleukin-6 was two-fold higher in MS compared with control subjects, consistently with an inflammatory state. Hypertriglyceridemia of MS subjects was aggravated postprandially with the HF and HP meals and was lowest after the HC meal, arguing against increased hepatic VLDL production. HDL-cholesterol of MS subjects remained low postprandially, whereas apolipoprotein (apo) A-II was higher than in control subjects. Unexpectedly, postprandial insulin and glucose responses were higher in MS compared with control subjects, with the HP meal inducing the greater effects.. The sustained postprandial hypertriglyceridemia of MS subjects after all meals suggests defective catabolism of triglyceride-rich lipoproteins. The greater postprandial increases in plasma insulin and glucose in MS relatively to control subjects indicate decreased insulin sensitivity, not revealed in the fasted state.

    Topics: Adult; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Double-Blind Method; Dyslipidemias; Ghrelin; Humans; Hypertriglyceridemia; Insulin; Interleukin-6; Male; Metabolic Syndrome; Obesity, Abdominal; Peptide YY; Postprandial Period

2010

Other Studies

3 other study(ies) available for peptide-yy and Dyslipidemias

ArticleYear
ADAR1 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice.
    American journal of physiology. Endocrinology and metabolism, 2021, 01-01, Volume: 320, Issue:1

    Obesity is an important independent risk factor for type 2 diabetes, cardiovascular diseases, and many other chronic diseases. The objective of this study was to determine the role of adenosine deaminase acting on RNA 1 (ADAR1) in the development of obesity and insulin resistance. Wild-type (WT) and heterozygous ADAR1-deficient (

    Topics: Adenosine Deaminase; Animals; Appetite; Body Composition; Diet, High-Fat; Dyslipidemias; Eating; Ghrelin; Glucose Tolerance Test; Insulin Resistance; Male; Mice; Mice, Knockout; Obesity; Peptide YY

2021
Ligilactobacillus Salivarius LCK11 Prevents Obesity by Promoting PYY Secretion to Inhibit Appetite and Regulating Gut Microbiota in C57BL/6J Mice.
    Molecular nutrition & food research, 2021, Volume: 65, Issue:17

    Obesity is a common disease worldwide and there is an urgent need for strategies to preventing obesity.. The anti-obesity effect and mechanism of Ligilactobacillus salivarius LCK11 (LCK11) is studied using a C57BL/6J male mouse model in which obesity is induced by a high-fat diet (HFD). Results show that LCK11 can prevent HFD-induced obesity, reflected as inhibited body weight gain, abdominal and liver fat accumulation and dyslipidemia. Analysis of its mechanism shows that on the one hand, LCK11 can inhibit food intake through significantly improving the transcriptional and translational levels of peptide YY (PYY) in the rectum, in addition to the eventual serum PYY level; this is attributed to the activation of the toll-like receptor 2/nuclear factor-κB signaling pathway in enteroendocrine L cells by the peptidoglycan of LCK11. On the other hand, LCK11 supplementation effectively reduces the Firmicutes/Bacteroidetes ratio and shifts the overall structure of the HFD-disrupted gut microbiota toward that of mice fed on a low-fat diet; this also contributes to preventing obesity.. LCK11 shows the potential to be used as a novel probiotic for preventing obesity by both promoting PYY secretion to inhibit food intake and regulating gut microbiota.

    Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Diet, High-Fat; Dyslipidemias; Eating; Enteroendocrine Cells; Gastrointestinal Microbiome; Intestines; Lactobacillaceae; Liver; Male; Mice, Inbred C57BL; Obesity; Peptide YY; Probiotics; Weight Gain

2021
Nutritional and endocrinologic evaluation of patients with craniopharyngioma.
    Clinical nutrition ESPEN, 2015, Volume: 10, Issue:6

    Lesions of hypothalamus or adjacent brain structures by the craniopharyngioma (CP) and/or its treatment, as well as changes in orexigenic and anorexigenic hormones, are possible pathogenic factors for the obesity observed in CP patients. This study assessed anthropometric measurements, food intake, and biochemical markers of CP patients.. Weight, height, skinfold thicknesses, circumferences, body composition, food intake evaluation, basal glucose, lipids, insulin, ghrelin, PYY, and HOMA-IR calculation were obtained from CP children (n = 10, 4F, aged 12 ± 4.2yr) and CP adults (n = 27,13F aged 42 ± 13 yr) and from 32 gender and age matched controls.. Overweight/obesity was observed in 51.4% of the patients at the diagnosis and increased to 86.5% at the time of the study. Obesity was more frequent in patients with grade 2 hypothalamic involvement. Most anthropometric measurements were similar in patients and controls. Caloric intake was lower in CP adults, without difference between children. Lipid intake was higher in CP patients. Carbohydrate and protein intakes were lower in CP children, with no difference between adult groups. There were no differences in micronutrients intake as well as in insulin and PYY levels, and HOMA-IR between patients and controls. HDL-c was lower in CP adults and ghrelin higher in CP children.. There is a high rate of overweight/obesity in CP patients at the diagnosis and throughout the follow-up period. Obesity was associated with degree of hypothalamic involvement but not with caloric intake. Obesity and a lipid rich diet may have contributed to the dyslipidemia observed in CP patients.

    Topics: Adolescent; Adult; Anthropometry; Biomarkers; Blood Glucose; Body Composition; Case-Control Studies; Child; Craniopharyngioma; Dyslipidemias; Eating; Energy Intake; Female; Ghrelin; Humans; Hypothalamus; Insulin; Lipids; Male; Middle Aged; Nutritional Status; Obesity; Peptide Hormones; Peptide YY; Pituitary Neoplasms; Time Factors; Young Adult

2015